Cancers & treatments·Comprehensive genomic profiling·Exome and genome sequencing

Tumour sequencing tests

25 tests from 14 laboratories side by side: whether they need tissue or blood, whether they read a chosen panel of genes, the whole exome, the exome plus the RNA, or only trace tumour DNA after treatment, what the report contains, and the regulatory status where it is certain. A blank cell means OnCo does not state it.

BostonGene Caris Life Sciences Exact Sciences (Abbott)Foundation Medicine (Roche)GRAIL Guardant Health Illumina Labcorp Myriad Genetics Natera NeoGenomics Personalis (Tempus)Strata Oncology Tempus AI

How to read this

Most tests here are laboratory-developed tests: run in one accredited laboratory in the United States under CLIA rules rather than approved as a kit. FDA approval applies to a specific version with named companion diagnostic claims, and CE marking to sale in Europe. Which test you get depends on your hospital, your country and your insurer; in England the NHS Genomic Medicine Service funds the tests in its directory. Ask the treating team which test was run and for the report itself; the report reader explains the values.

By scope

How much of the genome the test reads. Pick a scope to filter the table; pick a test for its page.

Exome plus transcriptome 4 tests

Reads the coding DNA and the RNA, so it also sees which genes are switched on and catches fusions.

BostonGene Tumor Portrait Caris MI Cancer Seek Caris MI Profile Exact Sciences OncoExTra

Exome 2 tests

Reads the protein-coding part of every gene, about one to two per cent of the genome.

Natera Altera Tempus xE

Targeted panel 13 tests

Reads a chosen set of cancer genes, usually a few hundred, at high depth.

Exact Sciences Oncotype DX Breast Recurrence Score FoundationOne CDx FoundationOne Heme FoundationOne Liquid CDx Guardant360 CDx Illumina TruSight Oncology 500 Illumina TruSight Oncology Comprehensive Labcorp OmniSeq INSIGHT Myriad myChoice CDx NeoGenomics NeoTYPE profiles StrataEXP StrataNGS Tempus xT and xT CDx

MRD (residual disease)4 tests

Looks in blood for traces of tumour DNA after treatment, to catch relapse early.

Guardant Reveal Natera Signatera NeoGenomics RaDaR Personalis NeXT Personal

Screening 2 tests

Looks in blood for signs of a cancer in someone without symptoms.

Galleri Guardant Shield

By sample

What the laboratory needs from you.

Tissue 13 tests

Needs a piece of the tumour, from a biopsy or surgery.

BostonGene Tumor Portrait Caris MI Cancer Seek Caris MI Profile Exact Sciences OncoExTra Natera Altera Tempus xE Exact Sciences Oncotype DX Breast Recurrence Score FoundationOne CDx Illumina TruSight Oncology Comprehensive Labcorp OmniSeq INSIGHT Myriad myChoice CDx StrataEXP StrataNGS

Blood 8 tests

Needs a blood draw and reads the tumour DNA circulating in it.

FoundationOne Liquid CDx Guardant360 CDx Guardant Reveal Natera Signatera NeoGenomics RaDaR Personalis NeXT Personal Galleri Guardant Shield

Tissue or blood 4 tests

Runs on tumour tissue or on blood, or offers a version of each.

FoundationOne Heme Illumina TruSight Oncology 500 NeoGenomics NeoTYPE profiles Tempus xT and xT CDx

By regulatory status

FDA approved8 CE marked3 Laboratory-developed test17 Research use only1

Read from each row's stated status; a test can carry more than one.

Technologies

Comprehensive genomic profiling Whole-exome & whole-genome sequencing Liquid biopsy (ctDNA)MRD / molecular residual disease testing Companion diagnostics

Sample

Scope

Company

Regulatory status

25 of 25 tests

Test		What it returns		EU status	Technologies
BostonGene Tumor Portrait The immune microenvironment classification is the distinctive part: it groups tumours by how immune cells are arranged, which BostonGene reports alongside the genomics.	BostonGene	Somatic mutations, copy number and fusions from whole exome sequencing of tumour and normal, gene expression from RNA sequencing, tumour mutational burden, microsatellite status, and a classification of the tumour's immune microenvironment. MSI-high TMB-high	Laboratory-developed test (CLIA laboratory)		Whole-exome & whole-genome sequencing Comprehensive genomic profiling
Caris MI Cancer Seek OnCo record	Caris Life Sciences	The FDA-approved whole exome and whole transcriptome assay, with companion diagnostic claims for specific drug and cancer pairs alongside the broader profile. ALK fusion BRAF class II and class III mutations BRAF V600E EGFR exon 19 deletion KRAS G12C KRAS G12D MSI-high PIK3CA mutation RAS wild-type RET fusion and RET mutation TMB-high Tumour	FDA approved (2024)		Whole-exome & whole-genome sequencing Companion diagnostics
Caris MI Profile	Caris Life Sciences	Whole exome and whole transcriptome sequencing of the tumour, with immunohistochemistry where relevant, reporting mutations, copy number, fusions, expression, tumour mutational burden, microsatellite status and loss of heterozygosity, matched to approved drugs and trials. 1p/19q codeletion BRAF fusion or rearrangement FGFR2 fusion or rearrangement FGFR3 alteration H3 K27M mutation HER2 IHC 3+HRD-positive MET amplification MET exon 14 skipping mutation MGMT promoter methylation MYCN amplification NRG1 gene fusion NTRK1/2/3 gene fusion PD-L1 CPS PDGFRA exon 18 mutation PTEN alteration TP53 mutation and del	Laboratory-developed test (CLIA laboratory); the FDA-approved version is MI Cancer Seek		Whole-exome & whole-genome sequencing Comprehensive genomic profiling RNA sequencing & expression profiling
Exact Sciences OncoExTra	Exact Sciences (Abbott)	Whole exome and whole transcriptome sequencing of tumour with matched normal, reporting mutations, copy number, fusions, expression, tumour mutational burden and microsatellite status. MSI-high NRG1 gene fusion NTRK1/2/3 gene fusion TMB-high	Laboratory-developed test (CLIA laboratory)		Whole-exome & whole-genome sequencing Comprehensive genomic profiling RNA sequencing & expression profiling
Natera Altera	Natera	Whole exome sequencing of the tumour reporting mutations, copy number and fusions, tumour mutational burden and microsatellite status, matched to therapies and trials; the same exome data seeds a Signatera panel. MSI-high TMB-high	Laboratory-developed test (CLIA laboratory)		Whole-exome & whole-genome sequencing Comprehensive genomic profiling
Tempus xE	Tempus AI	Whole exome sequencing of tumour and matched normal, reporting somatic and germline variants across the coding genome, tumour mutational burden and microsatellite status. TMB-high	Laboratory-developed test (CLIA laboratory)		Whole-exome & whole-genome sequencing
Exact Sciences Oncotype DX Breast Recurrence Score OnCo record Not a mutation test: it measures expression of 21 genes to predict recurrence risk and chemotherapy benefit.	Exact Sciences (Abbott)	A 21-gene expression Recurrence Score from 0 to 100 for early hormone receptor positive, HER2 negative breast cancer, estimating the benefit of adding chemotherapy to endocrine therapy. ER status	Laboratory-developed test (CLIA laboratory)		Gene-expression prognostic assays
FoundationOne CDx OnCo record	Foundation Medicine (Roche)	Substitutions, indels, copy number changes and selected rearrangements in 324 genes, plus tumour mutational burden and microsatellite status, with companion diagnostic claims for a long list of targeted drugs. 1p/19q codeletion AKT1 E17K mutation ALK fusion BRAF class II and class III mutations BRAF fusion or rearrangement BRAF V600E EGFR exon 19 deletion EGFR exon 20 insertion EGFR L858R EGFR T790M ESR1 mutation FGFR2 fusion or rearrangement FGFR3 alteration H3 K27M mutation HER2 IDH1 R132 mutation KRAS G12C KRAS G12D MET amplification MET exon 14 skipping mutation MSI-high MYCN amplification NRG1 gene fusion NTRK1/2/3 gene fusion PDGFRA exon 18 mutation PIK3CA mutation PTEN alteration RAS wild-type RET fusion and RET mutation ROS1 fusion TMB-high TP53 mutation and del Tumour	FDA approved (PMA P170019, 2017)	CE marked	Comprehensive genomic profiling Companion diagnostics
FoundationOne Heme	Foundation Medicine (Roche)	DNA sequencing of several hundred genes plus RNA sequencing of fusion genes for leukaemias, lymphomas, myeloma and sarcomas, from blood, bone marrow or tissue. BCR::ABL1 T315I BCR::ABL1 transcript FLT3-ITD FLT3-TKD IDH1 R132 mutation IDH2 mutation KIT D816V NPM1 mutation TP53 mutation and del	Laboratory-developed test (CLIA laboratory)		Comprehensive genomic profiling
FoundationOne Liquid CDx OnCo record	Foundation Medicine (Roche)	Alterations in more than 300 genes from cell-free DNA in a blood draw, including blood tumour mutational burden and microsatellite status, with companion diagnostic claims; a negative result does not rule out the alteration in tissue. AKT1 E17K mutation ALK fusion BRAF V600E EGFR exon 19 deletion EGFR L858R EGFR T790M ESR1 mutation FGFR2 fusion or rearrangement KRAS G12C MET amplification MET exon 14 skipping mutation MSI-high NTRK1/2/3 gene fusion PIK3CA mutation PTEN alteration ROS1 fusion TMB-high Tumour	FDA approved (PMA P190032, 2020)	CE marked	Liquid biopsy (ctDNA)Comprehensive genomic profiling Companion diagnostics
Guardant360 CDx OnCo record	Guardant Health	Mutations, amplifications and fusions in more than 50 genes from cell-free DNA, with companion diagnostic claims in lung and breast cancer; the wider laboratory Guardant360 reports more genes. AKT1 E17K mutation ALK fusion BRAF V600E EGFR exon 19 deletion EGFR exon 20 insertion EGFR L858R EGFR T790M ESR1 mutation HER2 KRAS G12C KRAS G12D MET amplification MET exon 14 skipping mutation PIK3CA mutation RAS wild-type RET fusion and RET mutation ROS1 fusion	FDA approved (PMA P200010, 2020)		Liquid biopsy (ctDNA)Comprehensive genomic profiling Companion diagnostics
Illumina TruSight Oncology 500	Illumina	A kit laboratories run themselves: DNA variants in 523 genes and RNA fusions in 55 genes, plus tumour mutational burden and microsatellite status; a cell-free DNA version exists for blood. MSI-high TMB-high	Research use only kit; the in vitro diagnostic version is TruSight Oncology Comprehensive		Comprehensive genomic profiling
Illumina TruSight Oncology Comprehensive OnCo record	Illumina	The in vitro diagnostic form of the TSO 500 content, reporting variants across the same gene set with companion diagnostic claims for fusion-directed drugs. ALK fusion BRAF class II and class III mutations BRAF fusion or rearrangement BRAF V600E EGFR exon 19 deletion EGFR exon 20 insertion EGFR L858R FGFR2 fusion or rearrangement FGFR3 alteration HER2 IDH1 R132 mutation KRAS G12C MET exon 14 skipping mutation NTRK1/2/3 gene fusion RET fusion and RET mutation ROS1 fusion Tumour	FDA approved (2024)	CE marked	Comprehensive genomic profiling Companion diagnostics
Labcorp OmniSeq INSIGHT	Labcorp	DNA and RNA sequencing across several hundred genes plus immune gene expression, reporting mutations, fusions, tumour mutational burden, microsatellite status and PD-L1 in one report. MSI-high PD-L1 CPS PD-L1 TPS TMB-high	Laboratory-developed test (CLIA laboratory)		Comprehensive genomic profiling Reference laboratories and companion-diagnostic testing
Myriad myChoice CDx OnCo record	Myriad Genetics	BRCA1 and BRCA2 status and a genomic instability score combining loss of heterozygosity, telomeric allelic imbalance and large-scale transitions, reported together as homologous recombination deficiency status. Germline BRCA1/2 pathogenic variant HRD-positive Tumour	FDA approved (2019) as a companion diagnostic for PARP inhibitors		Companion diagnostics Comprehensive genomic profiling
NeoGenomics NeoTYPE profiles	NeoGenomics	Cancer-specific DNA and RNA panels (solid tumour, lung, myeloid and others) reporting mutations, copy number and fusions, often combined with immunohistochemistry and FISH from the same laboratory. BCR::ABL1 transcript FLT3-ITD FLT3-TKD IDH1 R132 mutation IDH2 mutation KIT D816V NPM1 mutation TP53 mutation and del	Laboratory-developed tests (CLIA laboratory)		Comprehensive genomic profiling Reference laboratories and companion-diagnostic testing
StrataEXP	Strata Oncology	Quantitative gene-expression measurements of drug targets and an immunotherapy response score, meant to be run alongside StrataNGS to inform choice of immunotherapy and antibody-drug conjugates.	Laboratory-developed test (CLIA laboratory)		RNA sequencing & expression profiling Comprehensive genomic profiling
StrataNGS	Strata Oncology	Mutations, copy number, fusions, tumour mutational burden and microsatellite status from a targeted DNA and RNA panel designed to work on very small tissue samples. MSI-high TMB-high	Laboratory-developed test (CLIA laboratory)		Comprehensive genomic profiling
Tempus xT and xT CDx OnCo record	Tempus AI	Mutations, copy number and fusions across several hundred genes from tumour tissue with a matched normal sample, plus RNA sequencing for fusions, tumour mutational burden and microsatellite status; xT CDx carries companion diagnostic claims. 1p/19q codeletion AKT1 E17K mutation ALK fusion BRAF class II and class III mutations BRAF fusion or rearrangement BRAF V600E EGFR exon 19 deletion EGFR exon 20 insertion EGFR L858R ESR1 mutation FGFR2 fusion or rearrangement FGFR3 alteration Germline BRCA1/2 pathogenic variant H3 K27M mutation HER2 HRD-positive IDH1 R132 mutation IDH2 mutation KRAS G12C KRAS G12D MET amplification MET exon 14 skipping mutation MGMT promoter methylation MSI-high NRG1 gene fusion NTRK1/2/3 gene fusion PDGFRA exon 18 mutation PIK3CA mutation PTEN alteration RAS wild-type RET fusion and RET mutation ROS1 fusion TMB-high TP53 mutation and del Tumour	xT CDx FDA approved (2023); the laboratory xT assay is a laboratory-developed test		Comprehensive genomic profiling Companion diagnostics
Guardant Reveal OnCo record	Guardant Health	Presence or absence of circulating tumour DNA after surgery or during surveillance, using mutations and methylation without needing a tumour sample first, in colorectal, breast and lung cancer. ctDNA MRD positivity	Laboratory-developed test (CLIA laboratory)		MRD / molecular residual disease testing Liquid biopsy (ctDNA)
Natera Signatera OnCo record	Natera	A tumour-informed residual disease result: whole exome sequencing of the tumour and normal picks 16 patient-specific variants, which are then tracked in serial blood samples and reported as detected or not detected with a level. ctDNA MRD positivity	Laboratory-developed test (CLIA laboratory) with FDA Breakthrough Device designations		MRD / molecular residual disease testing Liquid biopsy (ctDNA)
NeoGenomics RaDaR OnCo record	NeoGenomics	A tumour-informed residual disease result: the tumour is sequenced first and a personalised panel of its variants is then tracked in blood over time. ctDNA MRD positivity	Laboratory-developed test (CLIA laboratory)		MRD / molecular residual disease testing Liquid biopsy (ctDNA)
Personalis NeXT Personal	Personalis (Tempus)	An ultra-sensitive tumour-informed residual disease measurement: whole genome sequencing of the tumour designs a panel of up to about 1,800 variants that is then tracked in blood, reported as tumour DNA level over time. ctDNA MRD positivity	Laboratory-developed test (CLIA laboratory)		MRD / molecular residual disease testing Liquid biopsy (ctDNA)Whole-exome & whole-genome sequencing
Galleri OnCo record In the NHS-Galleri randomised trial (Nature Medicine, 22 September 2026) about 1 in 100 tests were positive each year, 58.0, 50.4 and 45.8 percent of positives were cancer across three rounds, and the primary endpoint of fewer stage III/IV diagnoses was not met.	GRAIL	Cancer signal detected or not detected from cell-free DNA methylation, with a predicted cancer signal origin when a signal is found; a positive result leads to diagnostic work-up.	Laboratory-developed test (CLIA laboratory); premarket approval application submitted January 2026, FDA advisory committee 23 September 2026		Multi-cancer early detection (MCED)Liquid biopsy (ctDNA)DNA methylation profiling
Guardant Shield OnCo record	Guardant Health	A positive or negative result for colorectal cancer signal in cell-free DNA, for people at average risk aged 45 and over; a positive result leads to colonoscopy.	FDA approved (2024) as a primary colorectal cancer screening option		Liquid biopsy (ctDNA)

Laboratories in this table

BostonGene Caris Life Sciences Exact Sciences (Abbott)Foundation Medicine (Roche)GRAIL Guardant Health Illumina Labcorp Myriad Genetics Natera NeoGenomics Personalis (Tempus)Strata Oncology Tempus AI

Free routes to testing, including charity-funded sequencing programmes and the NHS directory, are on the free in oncology page. Companion diagnostic assays with FDA claims, by drug, are on the assays page.